Mogen Inc. Essay

EXECUTIVE SUMMARYIn 2006, Merrill Lynch become the lead book runner for a $5 billion convertible bond issue for MoGen, Inc., which was the single-largest convertible bond issuance in history. Merrill Lynchs Equity Derivatives Group needed to convert MoGens management of the best coupon rate and conversion premium for MoGen and the potential investors in the issue.BACKGROUNDMoGen, Inc was one of the leading company in the ergonomics industry. MoGen (Molecular Genetics) emerged with two of the first biologically derrived human therapeutic medicates that helped to offset the damaging effects from chemotherapy for cancer patients undergoing treatment. This products were the first blockbuster drugs to emerge from the nascent biotechnology industry. study ANALYSIS1.Strength Leading company in biotechnology industry.Succesfully treating the patient as well as making the company competitive leader in drug quality.Credit rating A+2.Opportunity Tren gaya hidup masyarakat yang mulai mementingk an kesehatanMunculnya berbagai gangguan kesehatan di zaman modern3.Threat Faced uncertainty of new product creation.Competitive threat of follow-on biologics or biosimilar began emerging.